Skip to main content

Table 3 Analysis of serum magnesium concentration (in mmol/L)

From: Higher bioavailability of magnesium citrate as compared to magnesium oxide shown by evaluation of urinary excretion and serum levels after single-dose administration in a randomized cross-over study

Time point Study product Mean (SD) Log-ANOVA
    Adj. mean ratio 95% CI p-value
Predose Biolectra 0.87 (0.042) 1.00 (0.98, 1.01) 0.5169
Verla 0.87 (0.042)
60 min Biolectra 0.88 (0.043) 1.01 (1.00, 1.02) 0.1991
Verla 0.88 (0.041)
2 h Biolectra 0.89 (0.040) 1.03 (1.01, 1.04) 0.0008*
Verla 0.92 (0.037)
3 h Biolectra 0.85 (0.041) 1.03 (1.02, 1.04) <.0001*
Verla 0.88 (0.040)
4 h Biolectra 0.88 (0.045) 1.03 (1.01, 1.04) 0.0016*
Verla 0.90 (0.040)
5 h Biolectra 0.87 (0.044) 1.03 (1.01, 1.04) 0.0036*
Verla 0.89 (0.043)
6 h Biolectra 0.86 (0.044) 1.02 (1.01, 1.04) 0.0026*
Verla 0.88 (0.039)
9 h Biolectra 0.89 (0.038) 1.02 (1.00, 1.03) 0.0979
Verla 0.90 (0.048)
24 h Biolectra 0.88 (0.049) 1.00 (0.99, 1.01) 0.8756
Verla 0.88 (0.043)
  1. CI confidence interval, Mg magnesium, SD standard deviation; Biolectra = Biolectra® Magnesium 300 mg Kapseln; Verla = Magnesium Verla® purKaps. Adjusted mean ratio, 95% CI and p-value are based on an ANOVA model with study product, sequence, period and subject within sequence as considered effects. Statistical significance at a level of 5% is given if the 95% confidence interval of the adjusted mean ratio does not include 1, respectively if the p-value is <0.05. Statistical significance is denoted by an asterisk (*)